Recursion Pharmaceuticals Inc (RXRX) Unusual Options Activity Today

Checking RXRX unusual options activity helps you spot when traders are making outsized bets on Recursion Pharmaceuticals Inc before the broader market catches on. Recursion Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor RXRX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching RXRX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking RXRX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and RXRX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.

The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Catalysts rarely arrive without a footprint, and RXRX unusual options activity is often where that footprint shows up first. Our scanner tracks Recursion Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at RXRX unusual options volume on the call side or chasing put sweeps, Recursion Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.